Experiences on the use of biological drugs in psoriatic arthritis-associated amyloidosis
Authors:
- K ImmonenKIK Immonen
- M KauppiMKM Kauppi
- M HakalaMHM Hakala
- 16 November 2010
- journal article
- letter
- Published by Taylor & Francis in Scandinavian Journal of Rheumatology
- Vol. 40 (3) , 236-238
Abstract
(2011). Experiences on the use of biological drugs in psoriatic arthritis-associated amyloidosis. Scandinavian Journal of Rheumatology: Vol. 40, No. 3, pp. 236-238. doi: 10.3109/03009742.2010.530294Keywords
This publication has 9 references indexed in Scilit:
- Tocilizumab dramatically ameliorated life-threatening diarrhea due to secondary amyloidosis associated with rheumatoid arthritisClinical Rheumatology, 2009
- Successful use of a humanized anti–interleukin‐6 receptor antibody, tocilizumab, to treat amyloid A amyloidosis complicating juvenile idiopathic arthritisArthritis & Rheumatism, 2006
- Classification criteria for psoriatic arthritis: Development of new criteria from a large international studyArthritis & Rheumatism, 2006
- Treatment of rheumatic inflammatory disease in 25 patients with secondary amyloidosis using tumor necrosis factor alpha antagonistsThe American Journal of Medicine, 2005
- Case Number 29: Hitting three with one strike: rapid improvement of psoriatic arthritis, psoriatic erythroderma, and secondary renal amyloidosis by treatment with infliximab (Remicade)Annals of the Rheumatic Diseases, 2004
- Cytostatic therapy for AA amyloidosis complicating psoriatic spondyloarthropathyRheumatology, 2003
- Mortality in rheumatoid arthritisSeminars in Arthritis and Rheumatism, 1995
- Mortality and causes of death in 398 patients admitted to hospital with ankylosing spondylitis.Annals of the Rheumatic Diseases, 1993
- Prediction of Creatinine Clearance from Serum CreatinineNephron, 1976